Kalderos Appoints Meghal Patel as Chief Product Officer
Kalderos, a healthcare technology company building the industry's only truly independent platform for drug discount management and revenue integrity, today announced the appointment of Meghal Patel as Chief Product Officer. Patel will leverage his deep background in data, AI, and healthcare technology to lead Kalderos' product strategy and execution, advancing the company's mission of delivering innovative, transparent drug pricing solutions.
Kalderos’ Industry-Leading Push for Transparency in 340B Drug Pricing Program Validated by Federal Court Ruling; Continued Delay in Implementation Hampers Meaningful Progress
Despite the U.S. District Court for the District of Columbia recently asserting that the 340B statute “explicitly contemplates” rebate models, those seeking to improve the 340B program’s transparency and ensure its efficacy remain in a holding pattern. This week, in response to years of efforts led by Kalderos and other 340B program stakeholders to implement a rebate model in the federal drug pricing program, the U.S. Department of Health and Human Services (HHS) submitted a proposed “340B Rebate Guidance” for review by the White House Office of Management and Budget. The substance of the proposed guidance was not shared publicly, meaning that all drug pricing stakeholders will need to wait up to 90 more days before getting much-needed clarity about the future integrity and sustainability of the 340B program.
